Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Life Science Equipment

Nymox Pharmaceutical Corp

+ Add to Watchlist

NY2:GR

0.491 EUR 0.111 29.21%

As of 13:02:59 ET on 02/27/2015.

Snapshot for Nymox Pharmaceutical Corp (NY2)

Open: 0.372 Day's Range: 0.329 - 0.501 Volume: 1,000
Previous Close: 0.380 52wk Range: 0.216 - 4.273 1-Yr Rtn: -87.70%

Stock Chart for NY2

No chart data available.
  • NY2:GR 0.501
  • 1D
  • 1M
  • 1Y
0.380
Interactive NY2 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NY2

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -
Est. PEG Ratio -
Market Cap (M EUR) 17.21
Shares Outstanding (M) 35.05
30 Day Average Volume 1,267
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/13/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NY2

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NY2

Nymox Pharmaceutical Corporation is a biopharmaceutical company. The Company is engaged in therapeutics in development for enlarged prostate (BPH), E. coli, Alzheimer's disease and other indications and diagnostics for tobacco exposure, Alzheimer's disease and other conditions.

Paul AverbackChairman/President/CEO/FounderAndre MonetteChief Financial Officer
Jack GemmellCIO/General CounselBrian DoyleSenior Mgr:Global Sales & Mktg
More Company Profile & Key Executives for NY2

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil